ANAVEX1066

ANAVEX1066 is a small molecule drug developed by Anavex Life Sciences. It acts as a mixed sigma-1 and sigma-2 receptor ligand, functioning as a modulator of both receptors. Preclinical studies have demonstrated its efficacy in animal models for neuropathic pain and visceral pain, where it restored nociceptive thresholds to normal levels in dose-dependent fashion without affecting normal gastrointestinal transit or causing significant behavioral side effects. The compound has also shown antitumor activity in preclinical settings. Its mechanism of action involves modulation of the sigma-1 (σ1) and sigma-2 (σ2) receptors, which are implicated in the regulation of pain signaling pathways and neuroprotection. ANAVEX1066 is being investigated primarily for the treatment of neuropathic pain, visceral pain, and other nervous system diseases[1][2][4].